Importantly, high expression of YB1 is reported to be associated with poor survival in ESCC patients, plays an oncogenic role in ESCC progression, and even is a potential target for ESCC therapy [10, 11]. This evidence concerns the gene YBX1 and esophageal squamous cell carcinoma.